Robbins Arroyo LLP is Investigating the Officers and Directors of Meridian Bioscience, Inc. (VIVO) on Behalf of Shareholders

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Meridian Bioscience, Inc. (NasdaqGS: VIVO) breached their fiduciary duties to shareholders. Meridian, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various infectious diseases worldwide.

View this press release on the firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/meridian-bioscience-inc/

Meridian Subsidiary is Under Investigation for Inaccurate Lead Tests

Investors of Meridian filed a securities class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 25, 2016 and July 13, 2017. According to the complaint, on March 24, 2016, Meridian announced its acquisition of Magellan Biosciences, Inc. and its wholly-owned subsidiary Magellan Diagnostics, Inc. (together "Magellan"). Although Meridian touted the accuracy, simplicity, and speed of Magellan's diagnostic products, their lead test kits actually provided inaccurate results. On May 17, 2017, the U.S. Food and Drug Administration ("FDA") warned that Magellan's lead tests may provide falsely low results and said that an inspection of Magellan's facility revealed that the company put patients at risk by failing to report that its tests could be inaccurate. On October 23, 2017, the FDA announced that it identified numerous violations of federal law, including marketing modified versions of the company's blood lead testing systems without the FDA's required clearance and failing to submit medical device reports to the FDA regarding discrepancies in test results. If Magellan fails to promptly correct its misdeeds, the FDA may take additional action, such as seizure, injunction, and civil monetary penalties.

Meridian Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005891/en/